IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation

NASDAQ:IDXX • US45168D1046

Current stock price

583.06 USD
-6.19 (-1.05%)
At close:
583.06 USD
0 (0%)
After Hours:

This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IDXX Profitability Analysis

1.1 Basic Checks

  • IDXX had positive earnings in the past year.
  • In the past year IDXX had a positive cash flow from operations.
  • Each year in the past 5 years IDXX has been profitable.
  • In the past 5 years IDXX always reported a positive cash flow from operatings.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 31.62%, IDXX belongs to the top of the industry, outperforming 98.93% of the companies in the same industry.
  • IDXX's Return On Equity of 65.99% is amongst the best of the industry. IDXX outperforms 99.47% of its industry peers.
  • IDXX has a Return On Invested Capital of 41.85%. This is amongst the best in the industry. IDXX outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 9.12%.
  • The 3 year average ROIC (37.64%) for IDXX is below the current ROIC(41.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROIC 41.85%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • With an excellent Profit Margin value of 24.62%, IDXX belongs to the best of the industry, outperforming 95.19% of the companies in the same industry.
  • IDXX's Profit Margin has improved in the last couple of years.
  • The Operating Margin of IDXX (31.60%) is better than 98.93% of its industry peers.
  • In the last couple of years the Operating Margin of IDXX has grown nicely.
  • IDXX's Gross Margin of 61.80% is fine compared to the rest of the industry. IDXX outperforms 63.64% of its industry peers.
  • IDXX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IDXX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
  • The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
  • Compared to 5 years ago, IDXX has less shares outstanding
  • The debt/assets ratio for IDXX has been reduced compared to a year ago.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 21.48 indicates that IDXX is not in any danger for bankruptcy at the moment.
  • IDXX has a Altman-Z score of 21.48. This is amongst the best in the industry. IDXX outperforms 94.12% of its industry peers.
  • IDXX has a debt to FCF ratio of 0.81. This is a very positive value and a sign of high solvency as it would only need 0.81 years to pay back of all of its debts.
  • IDXX has a Debt to FCF ratio of 0.81. This is amongst the best in the industry. IDXX outperforms 90.37% of its industry peers.
  • IDXX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • IDXX has a Debt to Equity ratio of 0.48. This is comparable to the rest of the industry: IDXX outperforms 40.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Altman-Z 21.48
ROIC/WACC4.76
WACC8.8%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • IDXX has a Current Ratio of 1.23. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
  • IDXX's Current ratio of 1.23 is on the low side compared to the rest of the industry. IDXX is outperformed by 86.10% of its industry peers.
  • IDXX has a Quick Ratio of 1.23. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IDXX has a worse Quick ratio (0.90) than 84.49% of its industry peers.
  • IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.9
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. IDXX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.18% over the past year.
  • The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
  • IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.42%.
  • IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.72% yearly.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.75% on average over the next years. This is quite good.
  • Based on estimates for the next years, IDXX will show a quite strong growth in Revenue. The Revenue will grow by 9.46% on average per year.
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y13.75%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y9.46%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. IDXX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 44.61 indicates a quite expensive valuation of IDXX.
  • IDXX's Price/Earnings ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 67.91% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.95. IDXX is valued rather expensively when compared to this.
  • The Price/Forward Earnings ratio is 39.37, which means the current valuation is very expensive for IDXX.
  • Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than the industry average as 70.05% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of IDXX to the average of the S&P500 Index (38.68), we can say IDXX is valued inline with the index average.
Industry RankSector Rank
PE 44.61
Fwd PE 39.37
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 69.52% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 73.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 44.37
EV/EBITDA 31.27
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IDXX may justify a higher PE ratio.
  • IDXX's earnings are expected to grow with 13.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.35
PEG (5Y)3.13
EPS Next 2Y13.11%
EPS Next 3Y13.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDXX Dividend Analysis

5.1 Amount

  • IDXX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDXX Fundamentals: All Metrics, Ratios and Statistics

IDEXX LABORATORIES INC

NASDAQ:IDXX (4/20/2026, 8:00:02 PM)

After market: 583.06 0 (0%)

583.06

-6.19 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02
Earnings (Next)05-05
Inst Owners95.6%
Inst Owner Change-0.12%
Ins Owners0.21%
Ins Owner Change1.92%
Market Cap46.31B
Revenue(TTM)4.30B
Net Income(TTM)1.06B
Analysts80.91
Price Target755.47 (29.57%)
Short Float %2.42%
Short Ratio3.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.79%
Min EPS beat(2)3.12%
Max EPS beat(2)6.47%
EPS beat(4)4
Avg EPS beat(4)4.78%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.3%
EPS beat(12)12
Avg EPS beat(12)4.65%
EPS beat(16)14
Avg EPS beat(16)3.71%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)1.03%
Revenue beat(4)2
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.74%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)-1.71%
PT rev (3m)-3.58%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 44.61
Fwd PE 39.37
P/S 10.76
P/FCF 44.37
P/OCF 39.18
P/B 28.84
P/tB 42.82
EV/EBITDA 31.27
EPS(TTM)13.07
EY2.24%
EPS(NY)14.81
Fwd EY2.54%
FCF(TTM)13.14
FCFY2.25%
OCF(TTM)14.88
OCFY2.55%
SpS54.19
BVpS20.21
TBVpS13.62
PEG (NY)3.35
PEG (5Y)3.13
Graham Number77.0998 (-86.78%)
Profitability
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROCE 61.77%
ROIC 41.85%
ROICexc 44.96%
ROICexgc 57.39%
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
FCFM 24.25%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
ROICexc(3y)42.76%
ROICexc(5y)42.28%
ROICexgc(3y)54.98%
ROICexgc(5y)55.56%
ROCE(3y)53.48%
ROCE(5y)55.19%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y1.33%
ROICexc growth 3Y7.31%
ROICexc growth 5Y1.49%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Debt/EBITDA 0.51
Cap/Depr 95.21%
Cap/Sales 3.21%
Interest Coverage 36.08
Cash Conversion 78.51%
Profit Quality 98.5%
Current Ratio 1.23
Quick Ratio 0.9
Altman-Z 21.48
F-Score8
WACC8.8%
ROIC/WACC4.76
Cap/Depr(3y)104.09%
Cap/Depr(5y)113.7%
Cap/Sales(3y)3.41%
Cap/Sales(5y)3.73%
Profit Quality(3y)93.28%
Profit Quality(5y)84.36%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y9.46%
EBIT growth 1Y20.53%
EBIT growth 3Y14.78%
EBIT growth 5Y14.44%
EBIT Next Year22.79%
EBIT Next 3Y14.89%
EBIT Next 5Y15.18%
FCF growth 1Y30.76%
FCF growth 3Y39.53%
FCF growth 5Y14.08%
OCF growth 1Y27.21%
OCF growth 3Y29.59%
OCF growth 5Y12.77%

IDEXX LABORATORIES INC / IDXX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


What is the valuation status for IDXX stock?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


What is the profitability of IDXX stock?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 44.61 and the Price/Book (PB) ratio is 28.84.


Can you provide the financial health for IDXX stock?

The financial health rating of IDEXX LABORATORIES INC (IDXX) is 8 / 10.